{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:29:31Z","timestamp":1784021371879,"version":"3.55.0"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>B\u2010rapidly accelerated fibrosarcoma (BRAF) inhibitor encorafenib alone and in combination with <jats:styled-content style=\"fixed-case\">MEK<\/jats:styled-content> inhibitor binimetinib improves survival in <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content>\u2010mutated melanoma patients. So far, the range of cutaneous adverse events has been characterized only for established <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> inhibitors (vemurafenib, dabrafenib) and <jats:styled-content style=\"fixed-case\">MEK<\/jats:styled-content> inhibitors (trametinib, cobimetinib).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to investigate cutaneous adverse events emerging in melanoma patients treated with encorafenib and binimetinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients treated with <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">MEK<\/jats:styled-content> inhibitors in clinical trials at the University Hospital of Zurich were identified. Frequency and features of cutaneous adverse events as well as their management were assessed based on the prospectively collected clinical and histopathological data. The events emerging during encorafenib and\/or binimetinib therapy were compared to other <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">MEK<\/jats:styled-content> inhibitors at the institution and in the literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most frequent cutaneous adverse events observed in patients treated with encorafenib alone (<jats:italic>n<\/jats:italic>\u00a0=\u00a024) were palmoplantar hyperkeratosis (54%), palmoplantar erythrodysesthesia (58%) and alopecia (46%). Drug\u2010induced papulopustular eruptions prevailed in patients with binimetinib monotherapy (<jats:italic>n<\/jats:italic>\u00a0=\u00a025). The most frequent cutaneous adverse events in patients treated with encorafenib\/binimetinib (<jats:italic>n<\/jats:italic>\u00a0=\u00a049) were palmoplantar hyperkeratosis (10%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to data published for established <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content>i, encorafenib monotherapy showed less hyperproliferative cutaneous adverse events. In contrast, palmoplantar hyperkeratosis and palmoplantar erythrodysesthesia seem to occur more often. The combination of encorafenib and binimetinib is well tolerated and induces few cutaneous adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.15363","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T17:05:41Z","timestamp":1542992741000},"page":"686-692","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B\u2010rapidly accelerated fibrosarcoma\u2010mutated advanced melanoma"],"prefix":"10.1111","volume":"33","author":[{"given":"N.P.","family":"Graf","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Koelblinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"},{"name":"Department of Dermatology Paracelsus Medical University Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Galliker","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Conrad","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Barysch","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mangana","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.F.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Goldinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32834fca92"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000242"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv297"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70012-9"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0369-8"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00087-X"},{"issue":"5","key":"e_1_2_5_11_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdx377.002","article-title":"Results of COLUMBUS Part 2: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF\u2010mutant melanoma","volume":"28","author":"Dummer R","year":"2017","journal-title":"Ann Oncol"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000426"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70413-8"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11155.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1745"},{"key":"e_1_2_5_17_1","first-page":"61","article-title":"Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients","volume":"29","author":"Vanneste L","year":"2015","journal-title":"JEADV"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8351"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.002"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058721"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13958"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0333"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt015"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12124"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2923"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203421"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70024-X"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30180-8"},{"issue":"15","key":"e_1_2_5_31_1","article-title":"A phase Ib\/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment","volume":"33","author":"Sullivan RJ","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"e_1_2_5_33_1","doi-asserted-by":"crossref","unstructured":"DummerR SandhuS HasselJCet\u00a0al. editors.LOGIC2: Phase 2 multi\u2010center open\u2010label study of sequential encorafenib\/binimetinib combination followed by a rational combination with targeted agents after progression to overcome resistance in adult patients with locally advanced or metastatic BRAF V600 melanoma. European Cancer Congress2015; Vienna.","DOI":"10.1016\/S0959-8049(16)31828-7"},{"key":"e_1_2_5_34_1","doi-asserted-by":"crossref","unstructured":"DummerR AsciertoP GogasHet\u00a0al. editors.Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF\u2010Mutant Melanoma; ASCO Annual Meeting 2018. ASCO Annual Meeting;2018; Chicago: J Clin Oncol.","DOI":"10.1200\/JCO.2018.36.15_suppl.9504"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016672037"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.12.040"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08833"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010017\u20100684\u2010x"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610456113"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1141"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.15363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.15363","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T02:49:09Z","timestamp":1694227749000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/jdv.15363"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15363","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"2018-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}